These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 21949656)

  • 1. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
    Subbian S; Tsenova L; O'Brien P; Yang G; Koo MS; Peixoto B; Fallows D; Dartois V; Muller G; Kaplan G
    PLoS Pathog; 2011 Sep; 7(9):e1002262. PubMed ID: 21949656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
    Koo MS; Manca C; Yang G; O'Brien P; Sung N; Tsenova L; Subbian S; Fallows D; Muller G; Ehrt S; Kaplan G
    PLoS One; 2011 Feb; 6(2):e17091. PubMed ID: 21364878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.
    Subbian S; Tsenova L; Holloway J; Peixoto B; O'Brien P; Dartois V; Khetani V; Zeldis JB; Kaplan G
    EBioMedicine; 2016 Feb; 4():104-14. PubMed ID: 26981575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
    Subbian S; Tsenova L; O'Brien P; Yang G; Koo MS; Peixoto B; Fallows D; Zeldis JB; Muller G; Kaplan G
    Am J Pathol; 2011 Jul; 179(1):289-301. PubMed ID: 21703411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
    Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
    Front Immunol; 2020; 11():680. PubMed ID: 32411131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid-induced control of Mycobacterium tuberculosis by primary human cells requires interleukin-1 receptor and tumor necrosis factor.
    Yamashiro LH; Eto C; Soncini M; Horewicz V; Garcia M; Schlindwein AD; Grisard EC; Rovaris DB; Báfica A
    Eur J Immunol; 2016 Aug; 46(8):1936-47. PubMed ID: 27230303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
    Subbian S; Koo MS; Tsenova L; Khetani V; Zeldis JB; Fallows D; Kaplan G
    Front Immunol; 2016; 7():238. PubMed ID: 27379099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
    Genestet C; Bernard-Barret F; Hodille E; Ginevra C; Ader F; Goutelle S; Lina G; Dumitrescu O;
    Tuberculosis (Edinb); 2018 Jul; 111():67-70. PubMed ID: 30029917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice.
    Negi S; Pahari S; Bashir H; Agrewala JN
    Eur J Immunol; 2020 Dec; 50(12):1976-1987. PubMed ID: 32673409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Mycobacterium tuberculosis clearance after the restoration of IFN-γ
    Kamboj D; Gupta P; Basil MV; Mohan A; Guleria R; Bhatnagar A; Mehta G; Kumar P; Saurabh A; Deepak R; Thakral D; Misra P; Tandon R; Gupta UD; Mitra DK
    Eur J Immunol; 2020 May; 50(5):736-747. PubMed ID: 32113187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for Tuberculosis Therapy.
    Pi J; Chen D; Wang J; Yang E; Yang J; Liu Y; Yu J; Xia J; Huang X; Chen L; Ruan Y; Xu JF; Yang F; Shen L
    Pharmacol Res; 2024 Oct; 208():107379. PubMed ID: 39218421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous latency in a rabbit model of pulmonary tuberculosis.
    Subbian S; Tsenova L; O'Brien P; Yang G; Kushner NL; Parsons S; Peixoto B; Fallows D; Kaplan G
    Am J Pathol; 2012 Nov; 181(5):1711-24. PubMed ID: 22960076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits.
    Subbian S; Bandyopadhyay N; Tsenova L; O'Brien P; Khetani V; Kushner NL; Peixoto B; Soteropoulos P; Bader JS; Karakousis PC; Fallows D; Kaplan G
    Cell Commun Signal; 2013 Aug; 11():60. PubMed ID: 23958185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
    Cynamon MH; Zhang Y; Harpster T; Cheng S; DeStefano MS
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2922-4. PubMed ID: 10582883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical disarming of isoniazid resistance in
    Flentie K; Harrison GA; Tükenmez H; Livny J; Good JAD; Sarkar S; Zhu DX; Kinsella RL; Weiss LA; Solomon SD; Schene ME; Hansen MR; Cairns AG; Kulén M; Wixe T; Lindgren AEG; Chorell E; Bengtsson C; Krishnan KS; Hultgren SJ; Larsson C; Almqvist F; Stallings CL
    Proc Natl Acad Sci U S A; 2019 May; 116(21):10510-10517. PubMed ID: 31061116
    [No Abstract]   [Full Text] [Related]  

  • 17. Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of
    Gupta PK; Jahagirdar P; Tripathi D; Devarajan PV; Kulkarni S
    Front Immunol; 2023; 14():1233630. PubMed ID: 37583694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China.
    Huo F; Lu J; Zong Z; Jing W; Shi J; Ma Y; Dong L; Zhao L; Wang Y; Huang H; Pang Y
    BMC Infect Dis; 2019 Aug; 19(1):689. PubMed ID: 31382930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Berberine as an Adjunct to TB Treatment.
    Ozturk M; Chia JE; Hazra R; Saqib M; Maine RA; Guler R; Suzuki H; Mishra BB; Brombacher F; Parihar SP
    Front Immunol; 2021; 12():656419. PubMed ID: 34745081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.
    Kumar R; Kolloli A; Singh P; Vinnard C; Kaplan G; Subbian S
    Front Cell Infect Microbiol; 2019; 9():450. PubMed ID: 32010638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.